Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS View Full Press Release Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress